Alessa Therapeutics
San Carlos, US · Founded 2018 · Delaware corporation · 17 employees on LinkedIn · 3 known investors
Alessa Therapeutics develops a proprietary drug-delivery platform for sustained and localized release of therapies to treat early-stage prostate cancer. The company is advancing Enolen, a drug-eluting implant designed to deliver enzalutamide directly to the prostate with fewer systemic side effects than existing treatments.
Founders & leadership
Alessa Therapeutics was founded in 2018 by Pamela Munster.
PM
Pamela MunsterFounder, Chief Scientific Advisor and Director
CG
Cam GallagherinExecutive
JM
John MaroneyExecutive
Board
ZC
ST
AM
RL
DC
PP
Investors · 3
Reported raises · per SEC filings
Form D private placements$31.6M disclosed across 3 rounds · 2019–2025
▶$25.4MraisedMay 2025 · 14 investors · Other Health CareRule 506(b)
▶$25.4MraisedMay 2025 · 14 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Zachary CollinsExecutive Officer
- Cam GallagherExecutive Officer, Director
- Steve TregayDirector
- Douglas CrawfordDirector
- Annie MitsakDirector
- Richard LimDirector
- Pamela MunsterDirector
- Offering amount
- $31.6M
- Amount sold
- $25.4M
- Minimum investment
- $1
- First sale
- Apr 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.3MraisedJan 2020 · 2 investors · Other Health CareRule 506(b)
▶$3.3MraisedJan 2020 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Peter ParkerDirector
- Pamela MunsterDirector
- John MaroneyExecutive Officer, Director
- Doug CrawfordDirector
- Offering amount
- $3.5M
- Amount sold
- $3.3M
- Minimum investment
- $1
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$3MraisedMar 2019 · 2 investors · Other Health CareRule 506(b)
▶$3MraisedMar 2019 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- John MaroneyExecutive Officer, Director
- Doug CrawfordDirector
- Pamela MunsterDirector
- Peter ParkerDirector
- Offering amount
- $3.5M
- Amount sold
- $3M
- Minimum investment
- $1
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlap
Azalea Therapeutics9 shared keywordsAzalea Therapeutics develops precision genome editing therapies that engineer T cells directly inside the patient's body to create cancer immunotherapies, using proprietary delivery vehicles to target and modify specific genetic loci without ex vivo cell manipulation.
Alesta8 shared keywordsAlesta Therapeutics is a biotech company developing oral small molecule therapies for rare diseases with limited treatment options. It focuses on targeted drugs suitable for all age groups, emphasizing safety, efficacy, and accessibility.
Kite Pharma7 shared keywordsKite Pharma develops CAR T-cell therapies for cancer patients, engineering the immune system's cells to target and attack cancer. Each therapy is individualized per patient through a multi-step manufacturing process.
Lisata Therapeutics, Inc.6 shared keywordsLisata develops drug delivery platform technology and therapies for solid tumors, enabling targeted anti-cancer drug delivery and immune system activation against cancer.
Exelixis6 shared keywordsExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
Solu5 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Companies competing with Alessa Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $405.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $393.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Alessa Therapeutics do?
- Alessa Therapeutics develops a proprietary drug-delivery platform for sustained and localized release of therapies to treat early-stage prostate cancer. The company is advancing Enolen, a drug-eluting implant designed to deliver enzalutamide directly to the prostate with fewer systemic side effects than existing treatments.
- Who founded Alessa Therapeutics?
- Alessa Therapeutics was founded by Pamela Munster in 2018.
- Who are Alessa Therapeutics's investors?
- Alessa Therapeutics's investors include Cure Ventures, Mission Bay Capital, Mission Biocapital.
- How much funding has Alessa Therapeutics raised?
- Alessa Therapeutics has disclosed $31.6M raised across 3 rounds.
- Where is Alessa Therapeutics headquartered?
- Alessa Therapeutics is headquartered in San Carlos, US.